In contrast to lower-risk MDS patients, the response to lenalidomide monotherapy is poor in patients with higher-risk del(5q) MDS and acute myeloid leukemia (AML), especially in those with TP53 mutations [7,8]. The gene discussed is TP53; the disease is myelodysplastic syndrome.